ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.75 USD
-0.21 (-7.09%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $2.76 +0.01 (0.36%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 21 - 40 ( 113 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
35th Annual ROTH MKM Conference - Consumer Track - March 12-14
Provider: Roth Capital Partners, Inc.
Analyst: KORANDA M
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Nicotinamide Riboside Cocktail Aids Alzheimer''s Cognition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Cash Flow Breakeven Status Possibly Imminent; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
3Q Results and 4Q Guidance Show Company on the Cusp of Positive EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Separating Manufacturing from Design the Next Step in INTC?s Turn-a-Round
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Strengthens Balance Sheet With Additional Cash, Bolsters Entry Into China
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue Miss; Revised Growth Trajectory; Lowering PT to $5.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
2Q Shows Prioritization of Path to Profitability Despite Rev Shortfall
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Asian Footprint Expansion; 1Q22 Financial Results; Modulating PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q1 Results Largely In-Line With Estimates, Despite Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Product and Patent Portfolio Expansion; 2021 Financials; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q4''21 and ''22 Outlooks Show Impact of Drop In Legal Spending
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage With Buy Rating and 12-Month Price Target of $7
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S